Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163

Critical Care Medicine

Volumn 34, Issue 10, 2006, Pages 2561-2566

  Møller, Holger Jon ^a   Moestrup, Søren K ^a,b   Weis, Nina ^c   Wejse, Christian ^a   Nielsen, Henrik ^d   Pedersen, Svend Stenvang ^e   Attermann, Jørn ^b   Nexø, Ebba ^a   Kronborg, Gitte ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hemophagocytosis; Prognosis; Sepsis; Serum marker

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD163 ANTIGEN; FERRITIN; NEOPTERIN; TRANSCOBALAMIN; UROKINASE;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL INFECTION; BLOOD CULTURE; CHEMICAL ANALYSIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENMARK; ERYTHROPHAGOCYTOSIS; FATALITY; FEMALE; HEMODIALYSIS; HUMAN; HYPOTENSION; INTENSIVE CARE; MACROPHAGE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK FACTOR; SEPSIS; STATISTICAL MODEL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; UNIVERSITY HOSPITAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BACTEREMIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; PROGNOSIS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

EID: 33748803031     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000239120.32490.AB     Document Type: Article

References (45)

1. Nielsen SV, Henrichsen J: Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94. Epidemiol Infect 1996; 117:411-416
2. Sankilampi U, Herva E, Haikala R, et al: Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland. Epidemiol Infect 1997; 118:7-15
3. Pedersen G, Schonheyder HC, Sorensen HT: Source of infection and other factors associated with case fatality in community-acquired bacteremia - A Danish population-based cohort study from 1992 to 1997. Clin Microbiol Infect 2003; 9:793-802
4. Balakrishnan I, Crook P, Morris R, et al: Early predictors of mortality in pneumococcal bacteraemia. J Infect 2000; 40:256-261
5. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35
6. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002; 20:197-216
7. Pasare C, Medzhitov R: Toll-like receptors: Linking innate and adaptive immunity. Microbes Infect 2004; 6:1382-1387
8. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
9. Gogos CA, Drosou E, Bassaris HP, et al: Proversus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J Infect Dis 2000; 181:176-180
10. Moestrup SK, Moller HJ: CD163: A regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004; 36:347-354
11. Kristiansen M, Graversen JH, Jacobsen C, et al: Identification of the haemoglobin scavenger receptor. Nature 2001; 409:198-201
12. Mosser DM: The many faces of macrophage activation. J Leukoc Biol 2003; 73:209-212
13. Droste A, Sorg C, Hogger P: Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 1999; 256:110-113
14. Sulahian TH, Hintz KA, Wardwell K, et al: Development of an ELISA to measure soluble CD163 in biological fluids. J Immunol Methods 2001; 252:25-31
15. Moller HJ, Peterslund NA, Graversen JH, et al: Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002; 99:378-380
16. Hintz KA, Rassias AJ, Wardwell K, et al: Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 2002; 72:711-717
17. Sulahian TH, Pioli PA, Wardwell K, et al: Cross-linking of FcR triggers shedding of the hemoglobin-haptoglobin scavenger receptor CD163. J Leukoc Biol 2004; 76:271-277
18. Timmermann M, Hogger P: Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med 2005; 39:98-107
19. Frings W, Dreier J, Sorg C: Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett 2002; 526:93-96
20. Hogger P, Sorg C: Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 2001; 288:841-843
21. Schaer DJ, Schleiffenbaum B, Kurrer M, et al: Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005; 74:6-10
22. Moller HJ, de Fost M, Aerts H, et al: Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004; 72:135-139
23. Hiraoka A, Horiike N, Akbar SM, et al: Soluble CD163 in patients with liver diseases: Very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 2005; 40:52-56
24. Murr C, Widner B, Wirleitner B, et al: Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3:175-187
25. Berdowska A, Zwirska-Korczala K: Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26:319-329
26. Moller HJ, Hald K, Moestrup SK: Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002; 62:293-299
27. Sidenius N, Sier CFM, Ullum H, et al: Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96:4091-4095
28. Nexo E, Christensen AL, Petersen TE, et al: Measurement of transcobalamin by ELISA. Clin Chem 2000; 46:1643-9
29. Goerdt S, Orfanos CE: Other functions, other genes: Alternative activation of antigen-presenting cells. Immunity 1999; 10:137-142
30. Mantovani A, Sozzani S, Locati M, et al: Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-555
31. Ruokonen E, Ilkka L, Niskanen M, et al: Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002; 46:398-404
32. Strohmaier W, Redl H, Schlag G, et al: D-erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med 1987; 15:757-760
33. Takahashi H, Tsuda Y, Takeuchi D, et al: Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med 2004; 32:1879-1885
34. Tsuda Y, Takahashi H, Kobayashi M, et al: CCL2, a product of mice early after systemic inflammatory response syndrome (SIRS), induces alternatively activated macrophages capable of impairing antibacterial resistance of SIRS mice. J Leukoc Biol 2004; 76:368-373
35. Castle SC: Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31:578-585
36. Plackett TP, Boehmer ED, Faunce DE, et al: Aging and innate immune cells. J Leukoc Biol 2004; 76:291-299
37. Moller HJ, Petersen PH, Rejnmark L, et al: Biological variation of soluble CD163. Scand J Clin Lab Invest 2003; 63:15-21
38. Strauss R, Neureiter D, Westenburger B, et al: Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients - A postmortem clinicopathologic analysis. Crit Care Med 2004; 32:1316-1321
39. Fehr J, De Vecchi P: Transcobalamin II: A marker for macrophage/ histiocyte proliferation. Am J Clin Pathol 1985; 84:291-296
40. Lambotte O, Cacoub P, Costedoat N, et al: High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 2003; 30:1027-1028
41. Emmenegger U, Reimers A, Frey U, et al: Reactive macrophage activation syndrome: A simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002; 132:230-236
42. Lee MH, Means RT Jr: Extremely elevated serum ferritin levels in a university hospital: Associated diseases and clinical significance. Am J Med 1995; 98:566-571
43. Wittenhagen P, Kronborg G, Weis N, et al: The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004; 10:409-415
44. Davis BH, Zarev PV: Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 2005; 63:16-22
45. Goldstein JI, Goldstein KA, Wardwell K, et al: Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. Atherosclerosis 2003; 170:325-332